Persistent Systems Partners with NVIDIA for AI Drug Discovery
Persistent Systems has announced a collaboration with NVIDIA to develop and deploy AI-powered solutions specifically for the healthcare and life sciences (HLS) sector. This partnership aims to accelerate computational drug discovery by integrating NVIDIA’s advanced AI technologies into Persistent Systems’ offerings. The company has developed a Generative Molecules and Virtual Screening solution, branded GenMolVS, which is a core component of this new initiative.
The GenMolVS platform is powered by NVIDIA’s BioNeMo platform and the NeMo Agent Toolkit. This integration allows Persistent Systems to leverage NVIDIA’s comprehensive AI capabilities for molecular simulation and discovery. The stated goal is to compress months-long drug discovery timelines to days by running simulations that model biological and chemical behavior prior to wet laboratory work.
Accelerating Biopharma Discovery with NVIDIA Technologies
Persistent Systems plans to utilize NVIDIA AI Enterprise, NVIDIA NIM microservices, and NVIDIA accelerated compute infrastructure to enhance its drug discovery solutions. Furthermore, the company intends to incorporate NVIDIA Nemotron open models to further develop the GenMolVS platform. Ganesh Nathella stated that the combination of GenMolVS with NVIDIA’s full-stack AI platform allows BioPharma clients to shift from lengthy experiments to AI-driven discovery without compromising scientific rigor.
John Fanelli added that the collaboration equips biopharma firms with production-grade agentic systems for molecular simulation. GenMolVS uses AI-driven molecular simulations to model the physical and chemical properties of molecules, enabling biopharma companies to conduct virtual screening and candidate prioritization before moving to physical laboratory experiments. Persistent Systems employs over 26,500 people across 18 countries.
Market Reaction and Future Outlook
Following the announcement, Persistent stock traded down 2.49 per cent at ₹4,523.30 on the NSE on Monday. This development occurs against a backdrop of broader weakness in the IT sector. Persistent Systems is a constituent of the Nifty Midcap 50 and the Dow Jones Sustainability World Index.
The collaboration focuses on accelerating computational drug discovery. The stated goal is to compress months-long drug discovery timelines to days by running simulations that model biological and chemical behavior prior to wet laboratory work. Persistent Systems plans to incorporate NVIDIA Nemotron open models to further develop the GenMolVS platform.
✨ Intelligent Curation Note
This article was processed by AI Universe’s Intelligent Curation system. We’ve decoded complex technical jargon and distilled dense data into this high-impact briefing.
Estimated time saved: ~1 minutes of reading.
Tools We Use for Working with AI:
